Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 3, 2015, Pages 545-550

  Rodby, Roger ^a   Umanath, Kausik ^b   Niecestro, Robert ^c   Jackson, James H ^d   Sika, Mohammed ^e   Lewis, Julia B ^e   Dwyer, Jamie P ^e  

^a RUSH UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Independent Consultant   (United States)

^d XCENDA   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

costs; dialysis; end stage renal disease; erythropoiesis stimulating agent; ferric citrate; hospitalization; iron

Indexed keywords

FERRIC CITRATE; HEMOGLOBIN; PHOSPHORUS; CHELATING AGENT; FERRIC ION;

ADULT; BINDING KINETICS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE ASSOCIATION; DRUG EFFICACY; END STAGE RENAL DISEASE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; ECONOMICS; HOSPITAL COST; HOSPITALIZATION; KIDNEY FAILURE, CHRONIC; METABOLISM; RENAL REPLACEMENT THERAPY; STATISTICS AND NUMERICAL DATA;

ADULT; CHELATING AGENTS; COST SAVINGS; FERRIC COMPOUNDS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHORUS; RENAL DIALYSIS;

EID: 84929252483     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.995169     Document Type: Review

References (17)

1. Umanath K, Sika M, Niecestro R, et al. Collaborative Study Group. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int 2013;17:67-74
2. Lewis JB, Sika M, Koury MJ, et al, for the Collaborative Study Group. Ferric citrate binds phosphorus and delivers iron to end-stage renal disease patients. J Am Soc Nephrol 2014. [Epub ahead of print]
3. Chaknos CM, Berns JS. Erythropoiesis-stimulating agents on trial: are higher dosages causing harm? Am J Kidney Dis 2013;61:6-8
4. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant 2014;29:255-9
5. U.S. Renal Data System, USRDS 2013 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2013
6. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50: 1694-9
7. Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998;79:299-305
8. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010;6:699-710
9. Fuller DS, Pisoni RL, Bieber BA, et al. The DOPPS Practice Monitor for US dialysis care: trends through December 2011. Am J Kidney Dis 2013;61:342-6
10. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372-9
11. Rodby R, Umanath K. Hsieh A, et al, for the Collaborative Study Group: phosphorus binding with ferric citrate reduces erythropoiesis-stimulating agent (ESA) and IV iron usage and cost in patients with ESRD. Am J Kid Dis 2014;63:A95
12. Rodby R, Hsieh A. Niecestro R, et al, for the Collaborative Study Group: phosphorus binding with ferric citrate reduces managed care costs through reduced use of iron and erythropoiesis-stimulating agents (ESAs). J Manage Care Pharm 2014;20:S53
13. Rooyakers T, Stroes E, Kooistra M, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002;32(Suppl 1):9-16
14. Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56
15. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
16. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76
17. Stowell CP, Jones SC, Enny C, et al. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine (Phila Pa 1976) 2009;34:2479-85